These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35372006)

  • 1. Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models.
    Heredia-Soto V; Escudero J; Miguel M; Ruiz P; Gallego A; Berjón A; Hernández A; Martínez-Díez M; Zheng S; Tang J; Hardisson D; Feliu J; Redondo A; Mendiola M
    Front Oncol; 2022; 12():862321. PubMed ID: 35372006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.
    Galmarini CM; Martin M; Bouchet BP; Guillen-Navarro MJ; Martínez-Diez M; Martinez-Leal JF; Akhmanova A; Aviles P
    BMC Cancer; 2018 Feb; 18(1):164. PubMed ID: 29415678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
    Elez E; Gomez-Roca C; Soto Matos-Pita A; Argiles G; Valentin T; Coronado C; Iglesias J; Macarulla T; Betrian S; Fudio S; Zaragoza K; Tabernero J; Delord JP
    Invest New Drugs; 2019 Aug; 37(4):674-683. PubMed ID: 30411218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay.
    Costales-Carrera A; Fernández-Barral A; Bustamante-Madrid P; Guerra L; Cantero R; Barbáchano A; Muñoz A
    Mar Drugs; 2019 Nov; 17(11):. PubMed ID: 31752287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of resistance to the microtubule-depolymerizing antitumor compound plocabulin.
    Pantazopoulou A; Galmarini CM; Peñalva MA
    Sci Rep; 2018 Jun; 8(1):8616. PubMed ID: 29872155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of the analogs of plocabulin and their preliminary structure-activity relationship study.
    Wang L; Li X; Cui H; Lei X; Liu H; Wang Q; Li Y
    Bioorg Med Chem Lett; 2021 Nov; 51():128355. PubMed ID: 34508844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors.
    Wang Y; Wozniak A; Wellens J; Gebreyohannes YK; Guillén MJ; Avilés PM; Debiec-Rychter M; Sciot R; Schöffski P
    Transl Oncol; 2020 Nov; 13(11):100832. PubMed ID: 32711367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
    Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
    Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the Marine Polyketide Plocabulin on Tumor Progression.
    Turrini E; Maffei F; Fimognari C
    Mar Drugs; 2022 Dec; 21(1):. PubMed ID: 36662211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
    Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
    J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interdimeric Curvature in Tubulin-Tubulin Complexes Delineates the Microtubule-Destabilizing Properties of Plocabulin.
    Navarrete KR; Jiménez VA
    J Chem Inf Model; 2020 Aug; 60(8):4076-4084. PubMed ID: 32687349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma.
    Chesnokov MS; Khan I; Park Y; Ezell J; Mehta G; Yousif A; Hong LJ; Buckanovich RJ; Takahashi A; Chefetz I
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33803586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plocabulin, a Novel Tubulin Inhibitor, Has Potent Antitumour Activity in Patient-Derived Xenograft Models of Soft Tissue Sarcoma.
    Wang Y; Wozniak A; Cornillie J; Avilés P; Debiec-Rychter M; Sciot R; Schöffski P
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.
    Haley J; Tomar S; Pulliam N; Xiong S; Perkins SM; Karpf AR; Mitra S; Nephew KP; Mitra AK
    Oncotarget; 2016 May; 7(22):32810-20. PubMed ID: 27147568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma.
    Zhong L; Liu X; Wang L; Liu Y; Zhang D; Zhao Y
    J Ovarian Res; 2022 Jan; 15(1):7. PubMed ID: 35027053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells.
    Ali A; Zhang F; Maguire A; Byrne T; Weiner-Gorzel K; Bridgett S; O'Toole S; O'Leary J; Beggan C; Fitzpatrick P; McCann A; Furlong F
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
    Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
    Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.